• In the second quarter of 2026, Celcuity Inc. reported a wider net loss of US$78.86 million and basic loss per share of US$1.44, even as it prepared for the commercial launch of its newly FDA‑approved breast cancer therapy Revtopik (also referred to as REVTORPYK).

• The FDA approval of Revtopik for HR‑positive, HER2‑negative advanced breast cancer, combined with its upgrade to Category 1 preferred status in NCCN guidelines and strong VICTORIA‑1 efficacy data, marks a key turning point as Celcuity shifts from a purely clinical focus toward potential commercial revenue.

• We'll now examine how Revtopik's FDA approval and NCCN Category 1 status could reshape Celcuity's previously pre‑commercial investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Celcuity Investment Narrative Recap

To own Celcuity today, you have to believe Revtopik can move from an FDA‑approved niche product to a meaningful commercial franchise, while the company reins in sizeable losses. The key near term catalyst is the first wave of Revtopik sales once shipments begin, and the main risk is that current operating losses, which widened to a Q2 2026 net loss of US$78.86 million, persist longer than investors are comfortable with.

The most relevant recent announcement is Revtopik's upgrade to NCCN Category 1 preferred status for second line HR‑positive, HER2‑negative breast cancer after endocrine progression. This endorsement, coming shortly after FDA approval, gives Celcuity a guideline foothold that could support the upcoming launch and any future label expansions the company pursues, including the planned supplemental NDA for the PIK3CA mutant population.

But with losses increasing and negative equity on the balance sheet, investors should also be aware that...

Read the full narrative on Celcuity (it's free!)

Celcuity's narrative projects $817.9 million in revenue and $267.5 million in earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.

Uncover how Celcuity's forecasts yield a $161.09 fair value , a 75% upside to its current price.

Exploring Other Perspectives

Before this approval, the most optimistic analysts were modeling US$1.4 billion of revenue and US$562.1 million of earnings by 2029, so Revtopik's launch could either validate that ambitious view or prompt a reset in expectations.

Explore 4 other fair value estimates on Celcuity - why the stock might be worth over 10x more than the current price!